Evaluation of apoptotic activity of newcondensed pyrazole derivatives

Journal of Physiology and Pharmacology

Volumn 64, Issue 1, 2013, Pages 115-123

  Toton, E ^a   Ignatowicz, E ^a   Bernard, M K ^a   Kujawski, J ^a   Rybczynska, M ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Apoptosis; Caspase; Cytotoxic activity; DNA intercalators; Poly ADP ribose polymerase; Pyrazole derivatives

Indexed keywords

CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PYRAZOLE DERIVATIVE; TOSIND; TOSPYRQUIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL STRAIN HT29; CELL STRUCTURE; CELL VIABILITY; CODON; COLON CANCER; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; P53 GENE; POINT MUTATION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 8; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DNA DAMAGE; HT29 CELLS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875769611     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nature Rev Mol Cell Biol 2008; 9: 378-390.
2. Kantari C, Walczak H. Caspase-8 and Bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 2011; 1813: 558-563.
3. Wurstle ML, Laussmann MA, Rehm M. The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res 2012; 318: 1213-1220.
4. Petros AM, Medek A, Nettesheim D G, et al. Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 2001; 98: 3012-3017.
5. Baldea I, Filip AG. Photodynamic therapy in melanoma - an update. J Physiol Pharmacol 2012; 63; 109-118.
6. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
7. Porter J, Payne A, de Candole B, et al. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. Bioorg Med Chem Lett 2009; 19: 230-233.
8. Bazgir A, Khanaposhtani MM, Soorki AA. One-pot synthesis and antibacterial activities of pyrazolo[4',3':5,6]pyrido[2,3-d]pyrimidine-dione derivatives. Bioorg Med Chem Lett 2008; 18: 5800-5803.
9. Rashad AE, Hegab MI, Abel-Megeid RE, Micky JA, Abdel-Megeid FM. Synthesis and antiviral evaluation of some new pyrazole and fused pyrazolopyrimidine derivatives. Bioorg Med Chem 2008; 16: 7102-7106.
10. Oliveira-Campos AMF, Sivasubramanian A, Rodrigues L, et al. Substituted pyrazolo[3,4-d]pyrimidines: microwave assisted, solvent free synthesis and biological evaluation. Helvetica Chim Acta 2008; 91: 472-478.
11. Migliara O, Raffa D, Plescia S, Cusimano M G, Carbone A. Synthesis and COX inhibition of 7-R1-8-R2-1-ethyl-3,4-dimeth yl-4, 10 - dih ydr o-1 H- pyr a z ol o[3,4-c][1,5] benzodiazocine-5,11-diones. ARKIVOC 2009; 2: 1-10.
12. Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation. Transplant Proc 2011; 43: 2439-2440.
13. Judson IR. Anthrapyrazoles: true successors to the anthracyclines? Anticancer Drugs 1991; 2: 223-231.
14. Sekine I, Fukuda H, Kunitoh H, Saijo N. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998; 28: 463-473.
15. Reszka K, Hartley JA, Lown JW. Photosensitization by selected anticancer agents. Biophys Chem 1990; 35: 313-323.
16. Umemura K, Mizushima T, Katayama M, Kiryu Y, Yamoro T, Andoh T. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-?]indole derivatives and their growth inhibitory activities. Mol Pharmacol 2002; 62: 873-880.
17. Hasinoff BB, Liang H, Wu X, et al. The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. Bioorg Med Chem 2008; 16: 3959-3968.
18. Palchaudhuri R, Hergenrother PJ. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 2007; 18: 497-503.
19. Shaw AY, Liau HH, Lu PJ, et al. 3,5-Diaryl-1H-pyrazole as a molecular scaffold for the synthesis of apoptosis-inducing agents. Bioorg Med Chem 2010; 18: 3270-3278.
20. Martinez R, Chacon-Garcia L. The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work. Curr Med Chem 2005; 12: 127-151.
21. Adjei AA. Current status of pyrazoloacridine as an anticancer agent. Invest New Drugs 1999; 17: 43-48.
22. Dipankar B, Hirakmoy C, Asish B, Abhijit C. 2-Pyrazoline: a pharmacologically active moiety. Int Res J Pharm App Sci 2011; 1: 68-80.
23. Pevarello P, Brasca MG, Amici R, et al. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead Finding. J Med Chem 2004; 47: 3367-3380.
24. Spreafico A, Schenone S, Serchi T, et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase. FASEB J 2008; 22: 1560-1571.
25. Naito H, Ohsuki S, Atsumi R, et al. Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. III. Synthesis and antitumor activity of 3-phenylpiperazinyl-1-trans-propenes. Chem Pharm Bull 2005; 53: 153-163.
26. Bertagnolli M, Eagle C, Zauber A, et al. Celecoxib for the prevention of sporadic colorectal adenomas. New Eng J Med 2006; 355: 873-884.
27. Makosza M, Kinowski A, Danikiewicz W, Mudryk B. Vicarious nucleophilic substitution in nitroquinolines1. Liebigs Ann Chem 1986; 1: 69-77.
28. Wojciechowski K, Makosza M. A facile synthesis of 3-sulfonyl-substituted indole derivatives. Synthesis 1986; 8: 651-653.
29. Garczarczyk D, Toton E, Biedermann V, et al. Signal transduction of constitutively active protein kinase C epsilon. Cell Signal 2009; 21: 745-752.
30. Hartmann A, Agurell E, Beevers C, et al. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 2003; 18: 45-51.
31. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004; 26: 249-261.
32. Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clin Cancer Res 2000; 6: 3885-3894.
33. Yamori T, Matsunaga A, Sato S, et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999; 59: 4042-4049.
34. Pan SL, Guh JH, Peng CY, et al. YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther 2005; 31: 35-42.
35. Chen CJ, Hsu MH, Huang LJ, et al. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem Pharmacol 2008; 75: 360-368.
36. Wang SW, Pan SL, Guh JH, et al. YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 2005; 312: 917-925.
37. Fan T, Han L, Cong R, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin 2005; 11: 719-727.
38. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
39. Hossini AM, Eberle J. Apoptosis induction by Bcl-2 proteins independent of the BH3 domain. Biochem Pharmacol 2008; 76: 1612-1619.
40. Kaufmann FC, Desnoyer S, Taviano Y, Davison NE, Poirier G G. Specific cleavage of PARP: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976-3985.
41. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997; 75: 337-349.
42. Pierzchalski P, Krawiec A, Gawelko J, Pawlik WW, Konturek SJ, Gonciarz M. Molecular mechanism of protection against chemically and g-radiation induced apoptosis in human colon cancer calls. J Physiol Pharmacol 2008; 59: 191-202.
43. Huang YT, Pan SL, Guh JH, et al. YC-1 suppresses constitutive nuclear factor-kB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 2005; 4: 1628-1635.
44. Ding XL, Zhang HY, Qi L, Zhao BX, Lv HS, Miao JY. Synthesis of novel pyrazole carboxamide derivatives and discovery of modulators for apoptosis or autophagy in A549 lung cancer cells. Bioorg Med Chem Lett 2009; 19: 5325-5328.
45. Strus M, Janczyk A, Gonet-Surowka A, et al. Effect of hydrogen peroxide of bacterial origin on apoptosis and necrosis of gut mucosa epithelial cells as a possible pathomechanism of inflammatory bowel disease and cancer. J Physiol Pharmacol 2009; 60: 55-60.
46. Han Z, Chatterjee D, He DM, et al. Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol Cell Biol 1995; 15: 5849-5857.
47. Gavathiotis E, Reyna DE, Bellairs JA, Leshchiner ES, Walensky LD. Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol 2012; 8; 639-645.